AC Immune SA (ACIU)
ACIUNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$2.31
-0.1300 (-5.33%) today
Regular session, Nov 10, 3:33 PM ET
- Market cap
- $235.10m
- P/E
- –
- EPS, last 4 quarters
- $-0.5000
- Dividend yield
- –
- Day range
- $2.30 to $2.39
- 52-week range
- $2.02 to $3.90
- Average volume
- 195.7k
- Previous close
- $2.44
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $9.67, +318.6% from here
Earnings
next estimate $-0.2300Next report
Dec 2025
+5.3%
Mar 2026
+5.0%
Jun 2026
+113.6%
Sep 2026
+27.3%
estimate reported, and the surprise
Financials
| Quarter | Mar 2016 | Jun 2016 |
|---|---|---|
| Revenue | $509.0k | $20.48m |
| Gross profit | $509.0k | $20.48m |
| Operating income | -$6.04m | $12.90m |
| Net income | -$6.45m | $13.40m |
News
8 latest- AC Immune SA Reports Third Quarter 2026 Financial Results and CHF 73.9 million Cash BalanceFintel · 6 days ago
- AC Immune (ACIU) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- INSM Stock Slides on CFO Exit, Reiterates '26 Sales ViewZacks · Oct 6, 2026
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowZacks · Oct 6, 2026
- PCRX Expands Exparel Commercial Reach in Europe Through Molteni DealZacks · Oct 6, 2026
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealZacks · Oct 5, 2026
- Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA ValidationZacks · Oct 5, 2026
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkZacks · Oct 5, 2026
The company
AC Immune (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company developing a pipeline of products, including both active immunotherapies and small molecules, targeting key misfolded proteins and pathways for the treatment of multiple neurodegenerative diseases. The company has a growing focus on its wholly owned proprietary clinical-stage programs, including: ACI-7104, an active immunotherapy targeting -synuclein (-syn) in Parkinson's disease; and ACI-19764, a small molecule inhibitor of the NLRP3 inflammasome. In addition, an early-stage small molecule development program targeting intracellular a-syn is advancing towards the clinic. ACIU has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding and >$4.5 billion in potential milestone payments, plus royalties from sales.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- acimmune.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.